Use of citral for treating focal segmental glomerulosclerosis

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8993637
APP PUB NO 20140343167A1
SERIAL NO

14251426

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NATIONAL DEFENSE MEDICAL CENTERNO 161 SEC 6 MINQUAN E RD NEIHU DIST TAIPEI 11490

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chang, Wen-Liang Taipei, TW 30 135
Chao, Kuo-Ping Chiayi County, TW 3 1
Chen, Ann Taipei, TW 31 75
Hua, Kuo-Feng I-Lan, TW 17 13
Hwa, Kuo-Yuan Taipei, TW 8 83
Ka, Shuk-Man Taipei, TW 25 24

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 30, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00